Daniel J Sargent

发表

Flexible Bayesian survival modeling with semiparametric time-dependent and shape-restricted covariate effects.

Bradley P Carlin, Thomas A Murray, Brian P Hobbs, 2016, Bayesian analysis.

Daniel J Sargent, Sin-Ho Jung, D. Sargent, 2014, Journal of biopharmaceutical statistics.

Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.

Bradley P Carlin, Brian P Hobbs, Daniel J Sargent, 2012, Bayesian analysis.

Rejoinder for “Meta‐analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling”

Debashis Ghosh, Daniel J Sargent, Jeremy M G Taylor, 2012, Biometrics.

Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials

Bradley P Carlin, Brian P Hobbs, Daniel J Sargent, 2011, Biometrics.

An adaptive dose‐finding design incorporating both toxicity and efficacy

Wei Zhang, Daniel J Sargent, Sumithra Mandrekar, 2006, Statistics in medicine.

An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles

Daniel J Sargent, Jun Yin, Sumithra J Mandrekar, 2018, Journal of biopharmaceutical statistics.

Impact of Copula Directional Specification on Multi-Trial Evaluation of Surrogate End Points

Daniel J Sargent, Hongwei Shang, Lindsay A Renfro, 2015, Journal of biopharmaceutical statistics.

A false‐discovery‐rate‐based loss framework for selection of interactions

Debashis Ghosh, Daniel J Sargent, Trivellore E Raghunathan, 2008, Statistics in medicine.

Bayesian adjusted R2 for the meta‐analytic evaluation of surrogate time‐to‐event endpoints in clinical trials

Bradley P Carlin, Daniel J Sargent, Qian Shi, 2012, Statistics in medicine.

Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.

Daniel J Sargent, Stuart G Baker, 2010, Journal of the National Cancer Institute.

Predictive biomarker validation in practice: lessons from real trials

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2010, Clinical trials.

Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program.

Daniel J Sargent, Daniel G Haller, Richard L Schilsky, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors.

Daniel J Sargent, John Hopper, Bharati Bapat, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.

Daniel J Sargent, Greg Yothers, Daniel G Haller, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimising the design of phase II oncology trials: the importance of randomisation.

Daniel J Sargent, Mark J Ratain, D. Sargent, 2009, European journal of cancer.

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Daniel J Sargent, Dongsheng Tu, Pierre Laurent-Puig, 2003, The New England journal of medicine.

Model‐based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: Methods and challenges

Daniel J Sargent, Rui Qin, Sumithra J Mandrekar, 2010, Statistics in medicine.

Clinical trial designs for predictive marker validation in cancer treatment trials.

Daniel J Sargent, Laurence Collette, L. Collette, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical Trial Designs for Predictive Biomarker Validation: One Size Does Not Fit All

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2009, Journal of biopharmaceutical statistics.

An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations

Daniel J Sargent, Sumithra J Mandrekar, Yue Cui, 2007, Statistics in medicine.

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Daniel J Sargent, Richard Simon, D. Sargent, 2017, The Lancet. Oncology.

Randomized phase II trials: time for a new era in clinical trial design.

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Integrating biomarkers in clinical trials

Daniel J Sargent, Marc Buyse, Stefan Michiels, 2011, Expert review of molecular diagnostics.

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

Daniel J Sargent, Somnath Sarkar, D. Sargent, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment.

Daniel J Sargent, Patrick J Heagerty, Holly Janes, 2015, Journal of the National Cancer Institute.

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Daniel J Sargent, Daniel G Haller, Marc Buyse, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers

Daniel J Sargent, Sumithra J Mandrekar, D. Sargent, 2013, Clinical trials.

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Daniel J Sargent, Greg Yothers, Qian Shi, 2013, Clinical colorectal cancer.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta‐analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling

Debashis Ghosh, Daniel J Sargent, Jeremy M G Taylor, 2012, Biometrics.

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Daniel J Sargent, Greg Yothers, Lindsay A Renfro, 2014, Journal of the National Cancer Institute.

New treatment options for colorectal cancer.

Daniel J Sargent, D. Sargent, C. Erlichman, 2004, The New England journal of medicine.

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Daniel J Sargent, D. Sargent, C. Fuchs, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.

Daniel J Sargent, Lindsay A Renfro, D. Sargent, 2014, Chinese clinical oncology.

Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Daniel J Sargent, Daniel G Haller, Joel E Tepper, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.

Daniel J Sargent, Qian Shi, Marc Buyse, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue.

Sridhar Ramaswamy, Daniel J Sargent, Oliver F Bathe, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternate Endpoints for Screening Phase II Studies

Daniel J Sargent, Dongsheng Tu, Lesley Seymour, 2009, Clinical Cancer Research.

The ARCAD clinical trials program: an update and invitation.

Daniel J Sargent, Marc Buyse, Alastair Matheson, 2012, The oncologist.

Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial.

Daniel J Sargent, Alan Herline, Mark Whiteford, 2015, JAMA.

Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer

Debashis Ghosh, Daniel J Sargent, Trivellore E Raghunathan, 2009, Biometrics.